Evaluation of efficacy and safety of the Qing Dai in patients with ulcerative colitis: A muticenter, double-blind, randomized controlled trial.
- Conditions
- ulcerative colitis
- Registration Number
- JPRN-UMIN000019103
- Lead Sponsor
- The Jikei University Kashiwa Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 68
Not provided
The patients with... 1. newly start or dose-up of 5-ASA within two weeks. 2. newly start or dose-up of steroids within two weeks. 3. newly start or dose-up of immunomodulators, such as azathioprine/6-methyl mercaptopurine within three months. 4. with biological products, such as Infliximab, and Adalimumab. 5. any herbal medicine containing the Qing Dai. 6. a possibility of pregnancy, during pregnancy, or lactating. 7. any mental illness that interfere to participate this trial. 8. active bacterial/fungal infections 9. history of myocardial infarction or unstable angina within three months. 10. uncontrollable hypertension 11. respiratery disease requiring a sustained oxigen administration.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.